Physician profile
Manisha Jhamb
NPI 1144457490
$43,692.94
in general payments reported to CMS, 2019-2025
13 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $172 · 2021: $935 · 2022: $7,146 · 2023: $17K · 2024: $16K · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,405 · Travel and Lodging: $5,021 · Food and Beverage: $3,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,217.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,405.00 |
| Travel and Lodging | $5,020.91 |
| Food and Beverage | $3,389.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,891.31 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $9,716.92 | 2023-2024 | Jardiance |
| Eli Lilly and Company | $5,239.85 | 2023 | |
| Novo Nordisk INC | $1,483.29 | 2025 | Ozempic |
| Vifor Pharma, INC. | $1,425.67 | 2020-2024 | Veltassa |
| Janssen Pharmaceuticals, INC | $1,000.41 | 2019-2024 | Xarelto |
| Travere Therapeutics, INC. | $636.04 | 2022-2024 | |
| Amgen INC. | $377.10 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.32 | 2021-2022 | |
| Shionogi INC | $206.64 | 2022-2025 | Fetroja |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $123.58 | 2019 | |
| Dexcom, INC. | $120.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Jhamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.